Friday, November 29, 2019
Genetron Health, a China-based precision oncology company that covers full-cycle cancer care, has obtained regulatory approval in China to launch its GENETRON S5 for clinical use. The approval of a new desktop medium-throughput semiconductor-based next generation sequencing (NGS) system---GENETRON S5, showcases Genetron Health’s ongoing commitment to providing early screening, diagnosis and treatment recommendations, as well as continuous monitoring and care services.
GENETRON S5 has obtained official approval from China’s National Medical Products Administration. This semiconductor-based NGS system detects changes in pH value in nucleotides. The unique advantage of GENETRON S5 lies in that it does not require fluorescence or camera scanning, resulting in faster, simpler and more cost-effective tests with a smaller sample size. GENETRON S5 leverages high speed semiconductor sequencing technology to produce high quality sequencing data, enabling laboratory technicians to go from DNA library to data in as little as 24 hours. This is based on Genetron Health’s patented One-Step Seq Method, which facilitates the preparation of high-quality libraries in just 1.5 hours from as little as 10ng input samples.
“The approval of GENETRON S5 provides another excellent choice for clinical laboratories and adds another powerful instrument for the standardization of molecular diagnosis. GENETRON S5 will deliver high-quality laboratory testing while providing data for clinical use and precision medicine in a much faster manner,” said Sizhen Wang, Co-founder and CEO of Genetron Health.
GENETRON S5 can be used in early screening, diagnosis, treatment guidance and continuous monitoring. With the diagnostic assays developed by Genetron Health, gliomas, lung cancer, urothelial cancer, breast cancer and thyroid cancer can be detected more effectively.
“Since our establishment, Genetron Health has explored new technology and areas of application while adapting to changes in the industry landscape to improve precision medicine in China. Working with clinical experts and our strategic partners, we have made progress in the field of in vitro diagnostic devices (IVD). The efficiency and speed of GENETRON S5 makes it possible for clinical organizations to help many more cancer patients,” Wang added.